Triple-Drug cocktail targets kidney cancer brain metastases
NCT ID NCT05048212
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a combination of three drugs—nivolumab, ipilimumab, and cabozantinib—can help people with kidney cancer that has spread to the brain. The study will enroll 20 participants who have not had prior treatment for their brain metastases. The main goal is to see if the drug combination can delay the growth of brain tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab, Ipilimumab, and Cabozantinib (three drugs given together)
What this could lead to
If it works, this could offer a new treatment option for people with kidney cancer that has spread to the brain, potentially delaying the growth of brain tumors.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug combination can cause serious side effects, and it is not yet known if it will improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact